That Erbitux trial is in second-line NSCLC. I don’t know if it’s on schedule to be completed in late 2006, but in any event we probably won’t get a report of the results until 2007.
As shown in the slides I referred to, PFE is running phase-2 trials in second-line NSCLC with COLY’s compound as well as phase-3 trials in first-line NSCLC. I don’t think it’s purposeful to try to compare the phase-2 results of this drug to the phase-2 results of Erbitux in NSCLC; we’ll have to wait for the results from phase-3. Regards, Dew
Market Data 
Markets 
AI
